Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 31Testicular Neoplasms 4Breast Neoplasms 4Vomiting 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Testicular Germ Cell Tumor 2Sezary Syndrome 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasms 2Nausea 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Neutrophilic, Chronic 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Prednisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperaldosteronism × Dexamethasone × Genitourinary × Clear all
NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

Phase 2 Completed
164 enrolled 22 charts
Genitourinary

Hyperaldosteronism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡